Valvular Atrial Fibrillation (VAF) is a specific subtype of atrial fibrillation characterized by the presence of significant heart valve disease. In individuals with VAF, irregular and often rapid heartbeats occur due to abnormal electrical signals in the atria, the upper chambers of the heart. The presence of valvular heart disease, such as mitral stenosis or a mechanical heart valve, increases the risk of developing VAF. Managing VAF poses unique challenges, as treatment strategies need to consider both the atrial fibrillation and the underlying valvular pathology. Healthcare professionals typically tailor their approach based on factors like the severity of the valve disease, overall health status, and individual patient considerations. Close monitoring and a collaborative, multidisciplinary approach are essential in addressing the complexities of Valvular Atrial Fibrillation.
Title : Pharmacological advancement in pulmonary arterial hypertension treatment - Contribution of treprostinil dry-powder formulation
Miroslav Radenkovic, University of Belgrade, Serbia
Title : Historical evolution from OPCAB to MIDCAB to mini OPCAB surgical technique and results
Federico Benetti, Benetti Foundation, Argentina
Title : Personalized and Precision Medicine (PPM) and PPN-guided cardiology practice as a unique model via translational applications and upgraded business modeling to secure human healthcare, wellness and biosafety
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Antibodies with functionality as a new generation of translational tools designed to monitor autoimmune myocarditis at clinical and subclinical stages
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation